What is the market's earnings forecast for The Joint next quarter?

What is The Joint's gross profit margin?

What is the revenue and EPS growth rate for The Joint year over year?

What were the key takeaways from The Joint's earnings call?

What were the key takeaways from The Joint’s earnings call?

What factors drove the changes in The Joint's revenue and profit?

What is The Joint's latest dividend and current dividend yield?

Did The Joint beat or miss consensus estimates last quarter?

- **Refranchising Success**: 87% of corporate clinics sold, nearing pure-play model with 48 remaining. 
- **Marketing Pivot**: Pain-relief messaging boosts SEO, AI search relevance, and early lead growth. 
- **Financial Health**: 2025 EBITDA up 13.9%, $11.3M share buybacks. 2026 guidance: EBITDA $12.5-13.5M, 19-21% margin. 
- **Growth Drivers**: Flexible pricing plans, national campaigns, and 25% IRR tech investments. 
- **Risk Management**: Cautious pricing tests, focusing on 70% of patients in $60-110K income bracket.

**【CEO Summary Section】**
- **Transformation Progress**: Completed 87% of refranchising, reducing corporate clinics from 135 to 48, with 3 buying groups in final stages. 
- **Marketing Shift**: Transitioned to pain-relief messaging, national SEO improvements, and AI-driven search optimizations. 
- **Patient Retention**: Introduced flexible pricing plans (e.g., Align 1 at $35/month) to reduce attrition, maintaining 9.7/10 patient satisfaction. 
- **Financial Highlights**: Q4 adjusted EBITDA up 7.8% to $3.6M; full-year EBITDA up 13.9% to $13M. 
- **Share Repurchases**: $11.3M in 2025, with $5.7M remaining under 2025 plan. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: System-wide sales $140M (-3.9% YoY), comp sales -3.8%, adjusted EBITDA $3.6M (+7.8%). 
- **2026 Guidance**: System-wide sales $519-552M, comp sales -3% to +3%, EBITDA $12.5-13.5M. 
- **Pure-Play Model**: Post-refranchising, targeting 11% revenue of system-wide sales, 19-21% EBITDA margin, and 13-15% net margin. 
- **Cost Efficiency**: G&A to drop from 64% to 40-42% of revenue, CapEx 3% of revenue. 

**【Q&A Highlights】**
- **Marketing & New Patients**: SEO improvements driving leads, but new patient growth lagging. National campaigns show early traction. 
- **Pricing Pilots**: $10 increase tests positive; cautious rollout pending data. 
- **Attrition Management**: Flexible plans (Align 1/2) reducing churn, with 75% patients waiting <5 mins. 
- **Capital Allocation**: 3% revenue for growth (martech, clinic UI), RD territory buybacks in negotiation. 
- **2026 Outlook**: Easier comps in H2, targeting sequential improvement in new patient trends.

The Joint Corp.(JYNT)-20260313-2025 Q4 Earnings call transcript

- **Revenue Recovery**: Continuing ops revenue +6%, EBITDA up 36% to $3.3M, driven by refranchising and cost cuts.
- **Tech Adoption**: Mobile app downloaded 178k times, 18% new patient engagement with gamified wellness tracking.
- **Pricing Strategy**: Testing 3 price tiers across 200 clinics to balance affordability with margin optimization.
- **Refranchising Momentum**: 40 corporate clinics sold, 33 in final negotiation stages, targeting 100% franchise model by 2026.
- **Financial Strength**: $29.7M cash, $12M buyback plan, and 2026 guidance for positive comps and EBITDA growth.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue from continuing operations increased 6%, driven by refranchising efforts and cost reductions. Adjusted EBITDA rose 36% to $3.3 million. 
- **AI & Technology**: Launched a patient-facing mobile app with 178,000 downloads, achieving 18% adoption among new patients. Testing gamification features like badges for engagement.
- **Refranchising Progress**: Sold 8 franchise licenses (vs. 7 last year), with 149 in development. Closed 3 corporate clinics and refranchised 40 so far.
- **Pricing Strategy**: Testing 3 price increase tiers across 200 clinics to balance affordability with margin optimization.
- **Marketing Shift**: Shifted $500/month per clinic from local to national campaigns, leveraging AI-driven search optimization.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $855k (vs. -$3.2M last year). Adjusted EBITDA from continuing ops up 36% to $1.4M. Unrestricted cash $29.7M.
- **Cost Efficiency**: Reduced G&A expenses 1%, cost of revenues down 6% via refranchising. Extended $12M stock buyback plan.
- **Guidance Update**: 2025 system-wide sales $530-534M, comp sales -1% to flat. 2026 target: 100% franchised model with improved margins.

**【Q&A Key Highlights】**
- **Refranchising Timeline**: 45 Southern California clinics in final negotiation stages. 33 remaining clinics under asset purchase agreements.
- **Pricing Pilot Results**: Testing 3 tiers of price increases across diverse geographies to gauge patient sensitivity.
- **App Engagement**: Early metrics show high patient experience scores, with features like credit card updates and treatment plan tracking.
- **Breakeven Improvement**: New clinics now reach breakeven in <1 year (vs. 2+ years prior), using preopening lead generation protocols.
- **Liquidity Management**: Extended $20M credit line maturity to 2027. Q3 share buybacks $2.3M, with $2.7M additional purchases post-quarter end.

The Joint Corp. (JYNT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: System-wide sales +2.6% YoY to $129.6M; comp sales +1.4%.
- **Profitability Boost**: Adjusted EBITDA +52% to $3.2M; net income $93K vs. $3.6M loss YoY.
- **Refranchising Success**: Sold 37 clinics, reducing corporate ownership to 8%; $11.1M deal with Joint Ventures.
- **Strategic Shifts**: Pain-focused marketing campaign, mobile app launch, and dynamic pricing strategy.
- **Updated Guidance**: Lowered system-wide sales to $530-550M; EBITDA raised to $10.8-11.8M.

**【CEO Summary Section】**
- **Q2 2025 Financial Highlights**: System-wide sales of $129.6 million (+2.6% YoY), comp sales +1.4%, and adjusted EBITDA of $3.2 million (+52% YoY). 
- **Refranchising Progress**: Reduced corporate clinics from 13% to 8% of portfolio by selling 37 clinics, including $11.1 million deal with Joint Ventures for 31 Arizona/New Mexico clinics. Acquired Northwest regional developer rights for $2.8 million.
- **Strategic Initiatives**: 
  - Launched "Life, Unpaused" pain-focused marketing campaign in July.
  - Introduced mobile app (10% adoption rate) with features like wellness plan reminders and gamification.
  - Implemented Kickstart plan for incremental adjustments and nominal price increases.

**【CFO Financial Commentary】**
- **Revenue & Profitability**: Continuing ops revenue +5% to $13.3 million; consolidated net income $93,000 vs. $3.6M loss YoY. Adjusted EBITDA +52% to $3.2 million.
- **Cost Management**: G&A expenses down 1% to $7.7 million; D&A up 18% due to software development.
- **Liquidity**: $29.8 million unrestricted cash; $5M stock buyback program authorized.
- **2025 Guidance Update**: 
  - System-wide sales: $530-550M (prev $550-570M)
  - Comp sales: Low single-digit growth (prev mid-single-digit)
  - Adjusted EBITDA: $10.8-11.8M (prev $10-11.5M)
  - Franchise openings: 30-35 (vs. 57 in 2024)

**【Q&A Key Highlights】**
- **Lowered Comp Guidance**: Soft new patient trends, macro headwinds, and tougher Q4 2024 comps. Shifting marketing to top-of-funnel and SEO optimization.
- **EBITDA Breakdown**: Continuing ops EBITDA $88,000; 80% of clinics now franchised.
- **Refranchising Proceeds**: $11.2M from clinic sales, $2.8M used for Northwest RD rights. Higher-performing AZ/NM clinics drove proceeds.
- **Pricing Strategy**: Nominal increases via Kickstart plan; exploring buy-now-pay-later options. No immediate broader price hikes.
- **RD Buybacks**: 15 RDs left (52% system coverage). Open to buybacks if value accretive.


The Joint Corp. (JYNT)-7 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Resilience**: Q1 2025 system-wide sales up 5% YoY to $132.6M, despite macroeconomic headwinds.
- **Franchise Expansion**: 87% of 969 clinics now franchise-owned; 93% of corporate clinics under LOI for refranchising.
- **Dynamic Pricing Growth**: Testing flexible pricing models, with H2 2025 prepaid visit pricing launch targeting double-digit million dollar impact.
- **Digital Transformation**: Mobile app beta successful; new marketing agency driving 4% March comp sales growth.
- **2025 Outlook**: System-wide sales $550-570M, mid-single-digit comp growth, and $10-11.5M adjusted EBITDA.
- **Long-Term Profitability**: 2026+ margin expansion via reduced G&A and royalty-based revenue from refranchising.

**【CEO Summary Section】**
- **System-wide sales growth**: Q1 2025 system-wide sales reached $132.6 million, up 5% YoY, driven by resilience in the chiropractic care market.
- **Franchise expansion progress**: 93% of corporate clinics under LOI, with plans to exit 2025 as a pure-play franchisor. Franchise clinics now represent 87% of total network (969 clinics).
- **Dynamic pricing strategy**: Testing flexible pricing models for wellness plans and acute care packages, with prepaid visit pricing launching in H2 2025.
- **Digital transformation**: Mobile app beta testing successful; expected launch by June 30, 2025. New marketing agency enhancing SEO and user-generated content.
- **Operational initiatives**: Inaugural Chiropractic Elite Academy planned for 2025 to strengthen doctor training and patient care standards.

**【CFO Financial Commentary】**
- **Q1 2025 Financial Highlights**: 
  - Revenue: $13.1 million (7% YoY growth)
  - Adjusted EBITDA: $46,000 (vs. $425,000 in Q1 2024)
  - Franchise license sales: 9 licenses (down from 15 YoY)
  - Franchise clinic openings: 5 new, 2 refranchised
- **Cost Management**: G&A expenses reduced to 53% of revenue (from 60% YoY). Selling & marketing expenses increased to $3.5 million due to dual agency transition.
- **2025 Guidance**: 
  - System-wide sales: $550-570 million
  - Comp sales: Mid-single-digit growth
  - Adjusted EBITDA: $10-11.5 million
  - Franchise openings: 30-40 (excluding refranchised clinics)
- **Long-term Vision**: 2026+ profitability improvement through reduced G&A, royalty-based revenue, and refranchising completion.

**【Q&A Key Highlights】**
- **Patient Metrics**: 
  - New patient leads impacted by macroeconomic uncertainty
  - Retention rates stable at historical levels
- **Pricing Impact**: 
  - Single-visit price increase (4% of sales) implemented
  - Additional pricing tests in H2 2025, targeting double-digit million dollar impact
- **Marketing Efficiency**: 
  - Dual agency costs ($3.5M Q1) expected to normalize in Q3
  - New digital strategy driving 4% March comp sales growth
- **Refranchising Timeline**: 
  - 93% of corporate clinics in due diligence
  - Target: complete refranchising by end-2025
- **Macro Risk Mitigation**: 
  - Pain-centric marketing focusing on chronic conditions (74% of new patients cite pain)
  - Wellness plan promotions (e.g., $45 first month) driving long-term retention

The Joint Corp. (JYNT)-8 May 25-2025 Q1 Earnings call transcript

- **Strategic Refocus**: Transitioning to pure-play franchisor with 125 corporate clinics under LOI, targeting $550-570M system-wide sales in 2025. 
- **Revenue Momentum**: 9% system-wide sales growth in 2024, Q4 comp sales turning positive for mature clinics. 
- **Cost Efficiency**: 2025 focus on reducing G&A expenses, with EBITDA guidance of $10-11.5M. 
- **Dynamic Pricing**: Testing incremental price hikes (e.g., +10% walk-in rate) to offset inflation, aiming for 1.5-2% comp from pricing. 
- **Growth Catalysts**: Mobile app launch Q2 2025, digital marketing expansion, and refranchising-driven margin improvement.

**【CEO Strategic Overview】**
- **Pure-Play Franchisor Transition**: Committed to refranchising all 125 corporate clinics, with the majority under LOI, to focus on becoming a world-class franchisor. 
- **2024 Performance**: System-wide sales grew 9% to $530.3M, Q4 comp sales for mature clinics turned positive after negative 2% in Q3. 
- **2025 Growth Plan**: Target $550-570M system-wide sales, mid-single-digit comp growth, and $10-11.5M adjusted EBITDA. 
- **Key Initiatives**: Dynamic pricing (e.g., walk-in rate increase), digital marketing expansion, and mobile app launch Q2 2025.

**【CFO Financial Breakdown】**
- **Q4 2024 Results**: Continuing ops revenue $14.4M (+14%), adjusted EBITDA $2.1M. Consolidated EBITDA $3.3M (-17% YoY due to refranchising transition). 
- **Cost Rationalization**: 2025 focus on reducing G&A expenses as clinics shift to franchise model. 
- **2025 Guidance**: Royalty/fee revenue expected to replace $70M+ in corporate clinic sales, with EBITDA margin improvement post-refranchising. 
- **Balance Sheet**: $25.1M cash, $20M credit line, and $9.1M NOL carryforward.

**【Q&A Key Takeaways】**
- **Consumer Behavior**: Q1 sales consistent with Q4 trend, slight attrition in January due to macro uncertainty. 
- **Pricing Strategy**: Testing incremental price increases (e.g., walk-in rate +10%) to offset inflation, targeting 1.5-2% comp from pricing. 
- **Franchisee Support**: 80% of active members on standard pricing, 20% on legacy rates; dynamic revenue management to optimize per-visit value. 
- **New Revenue Streams**: Exploring pediatric chiropractic, retail products, and B2B partnerships, with focus on core growth in 2025.


Actual												0.06	0.01	0.11	0.72	0.16	0.18	0.13	0.01	-0.01	0.02	0.03	0.04	0.15	-0.01	-0.05	-0.75	0.06	-0.24	-0.21	-0.18	-0.03	-0.0528	0.02	0.06
Forecast												0.065	-0.1267	0.025	0.1367	0.048	0.055	0.0467	0.055	0.0417	0.0133	0.055	0.075	-0.006	0.0126	0.018	0.012	0.005	-0.0178	0.0081	0.01	0.0025	-0.0433	0.0197	0.04
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7.69%	+107.89%	+340.00%	+426.70%	+233.33%	+227.27%	+178.37%	-81.82%	-123.98%	+50.38%	-45.45%	-46.67%	+2600.00%	-179.37%	-377.78%	-6350.00%	+1100.00%	-1248.31%	-2692.59%	-1900.00%	-1300.00%	-21.94%	+1.52%	+50.00%

JYNT

JYNT fundamentals

JYNT Q4 2025 Earnings

Earnings Call

You can ask Aime

JYNT

JYNT fundamentals

JYNT Q4 2025 Earnings

Earnings Call

JYNT Earnings Call Summary for Q4/20255:00 PM on Mar 12, 2026

JYNT Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

JYNT Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

JYNT Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

JYNT Earnings Call Summary for Q4/20245:00 PM on Mar 13, 2025

You can ask Aime